Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...
HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Hosted on MSN3h
The Handmaid's Tale Sequel Show Casts Its Young Protagonist With A Connection To GileadHulu’s The Testaments casts its Daisy, a Canadian teen whose world is upended when she discovers her hidden connection to ...
Despite there being an overall trend toward better representation, Dames 4 Games hopes for a world where Black/female-led ...
The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...
(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback